butyric acid has been researched along with Liver Failure, Acute in 2 studies
Butyric Acid: A four carbon acid, CH3CH2CH2COOH, with an unpleasant odor that occurs in butter and animal fat as the glycerol ester.
butyrate : A short-chain fatty acid anion that is the conjugate base of butyric acid, obtained by deprotonation of the carboxy group.
butyric acid : A straight-chain saturated fatty acid that is butane in which one of the terminal methyl groups has been oxidised to a carboxy group.
Liver Failure, Acute: A form of rapid-onset LIVER FAILURE, also known as fulminant hepatic failure, caused by severe liver injury or massive loss of HEPATOCYTES. It is characterized by sudden development of liver dysfunction and JAUNDICE. Acute liver failure may progress to exhibit cerebral dysfunction even HEPATIC COMA depending on the etiology that includes hepatic ISCHEMIA, drug toxicity, malignant infiltration, and viral hepatitis such as post-transfusion HEPATITIS B and HEPATITIS C.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, F | 1 |
| Wang, LK | 1 |
| Li, X | 1 |
| Wang, LW | 1 |
| Han, XQ | 1 |
| Gong, ZJ | 1 |
| Rudnick, DA | 1 |
| Dietzen, DJ | 1 |
| Turmelle, YP | 1 |
| Shepherd, R | 1 |
| Zhang, S | 1 |
| Belle, SH | 1 |
| Squires, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center Group to Study Acute Liver Failure in Children[NCT00986648] | 158 participants (Actual) | Observational | 2000-01-31 | Completed | |||
| A Multi-center Study of the Safety and Efficacy of N-acetylcysteine in the Treatment of Acute Liver Failure in Pediatric Patients Not Caused by Acetaminophen.[NCT00248625] | Phase 3 | 184 participants (Actual) | Interventional | 2000-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00248625)
Timeframe: Within 1 year of randomization
| Intervention | percentage of participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 45 |
| Placebo | 35 |
(NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | Participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 20 |
| Placebo | 21 |
(NCT00248625)
Timeframe: Randomization to hospital discharge
| Intervention | days (Median) |
|---|---|
| N-acetylcysteine (NAC) | 103 |
| Placebo | 21 |
Survival without liver transplantation (NCT00248625)
Timeframe: One year following randomization
| Intervention | participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 33 |
| Placebo | 49 |
Spontaneous survival without transplant plus survival following transplantation (NCT00248625)
Timeframe: One year following randomization
| Intervention | Participants (Number) |
|---|---|
| N-acetylcysteine (NAC) | 68 |
| Placebo | 76 |
The length of ICU stay was categorized as number of days in ICU within 7 days of randomization, unless participant either died or received an LTx within this time period. Special categories were created for these cases. (NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 0 days | 1 day | 2 days | 3 days | 4 days | 5 days | 6 days | 7 days | underwent LTx w/i 7 days of randomization | died w/o LTx w/i 7 days of randomization | |
| N-acetylcysteine (NAC) | 29 | 3 | 3 | 2 | 1 | 4 | 5 | 9 | 28 | 8 |
| Placebo | 34 | 4 | 4 | 0 | 3 | 3 | 3 | 14 | 22 | 5 |
West Haven Criteria for hepatic encephalopathy (Grade 0 - IV ) is used for participants > 3 year of age. Coma grade IV indicates a participant who is comatose , with no reflexes, is decerebrate and has abnormal EEG changes with very slow delta activity. For participants less than 3 years the Whittington Scale was used. The Whittington scale does not use EEG changes and has only 3 levels, early (grades I and II), Mid (III) with somnolence, stupor, combativeness and Late (IV) for participants who are comatose with absent reflexes and decerebrate or decorticate posturing. (NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 | I | II | III | IV | |
| N-acetylcysteine (NAC) | 28 | 16 | 20 | 15 | 11 |
| Placebo | 27 | 21 | 19 | 17 | 6 |
(NCT00248625)
Timeframe: Within 7 days of randomization
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| 0 | 1 | 2 | 3 | 4 | |
| N-acetylcysteine (NAC) | 44 | 21 | 15 | 11 | 1 |
| Placebo | 46 | 23 | 12 | 8 | 3 |
2 other studies available for butyric acid and Liver Failure, Acute
| Article | Year |
|---|---|
Sodium butyrate protects against toxin-induced acute liver failure in rats.
Topics: Animals; Biomarkers; Butyric Acid; Chemical and Drug Induced Liver Injury; Cytoprotection; Disease M | 2014 |
Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric acute liver failure.
Topics: Adipates; Adolescent; Animals; Biomarkers; Butyric Acid; Child; Child, Preschool; Female; Hepatectom | 2009 |
Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric acute liver failure.
Topics: Adipates; Adolescent; Animals; Biomarkers; Butyric Acid; Child; Child, Preschool; Female; Hepatectom | 2009 |
Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric acute liver failure.
Topics: Adipates; Adolescent; Animals; Biomarkers; Butyric Acid; Child; Child, Preschool; Female; Hepatectom | 2009 |
Serum alpha-NH-butyric acid may predict spontaneous survival in pediatric acute liver failure.
Topics: Adipates; Adolescent; Animals; Biomarkers; Butyric Acid; Child; Child, Preschool; Female; Hepatectom | 2009 |